GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » PB Ratio

AVANIR Pharmaceuticals (FRA:AV2B) PB Ratio : 13.12 (As of May. 20, 2024)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-20), AVANIR Pharmaceuticals's share price is €14.37. AVANIR Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2014 was €1.10. Hence, AVANIR Pharmaceuticals's PB Ratio of today is 13.12.

The historical rank and industry rank for AVANIR Pharmaceuticals's PB Ratio or its related term are showing as below:

FRA:AV2B' s PB Ratio Range Over the Past 10 Years
Min: 0.78   Med: 11.24   Max: 202.67
Current: 12.03

During the past 13 years, AVANIR Pharmaceuticals's highest PB Ratio was 202.67. The lowest was 0.78. And the median was 11.24.

FRA:AV2B's PB Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.04 vs FRA:AV2B: 12.03

During the past 12 months, AVANIR Pharmaceuticals's average Book Value Per Share Growth Rate was 1075.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 35.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 17.40% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of AVANIR Pharmaceuticals was 357.90% per year. The lowest was -72.30% per year. And the median was 4.00% per year.

Back to Basics: PB Ratio


AVANIR Pharmaceuticals PB Ratio Historical Data

The historical data trend for AVANIR Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals PB Ratio Chart

AVANIR Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.25 5.29 12.63 34.31 8.57

AVANIR Pharmaceuticals Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.31 53.86 20.91 13.59 8.57

Competitive Comparison of AVANIR Pharmaceuticals's PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVANIR Pharmaceuticals's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's PB Ratio falls into.



AVANIR Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

AVANIR Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2014)
=14.37/1.095
=13.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


AVANIR Pharmaceuticals  (FRA:AV2B) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


AVANIR Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines